Intravenous immunoglobulin (IVIg) preparations are widely used for anti-inflammatory therapy of autoimmune and systemic inflammatory diseases. Hyperimmunoglobulins enriched in neutralizing antibodies against viruses can, in addition to their virus-neutralizing activity, also exert immunomodulatory activity. Previously, we observed that Cytotect®, an anti-CMV hyperimmunoglobulin, was less effective in suppressing human T-cell responses in vitro compared to Hepatect® CP, an anti-HBV hyperimmunoglobulin. We hypothesized that the poor immunomodulatory activity of Cytotect® results from treatment with β-propiolactone during the manufacturing process. The manufacturer of these hyperimmunoglobulins has now introduced a new anti-CMV hyperimmunoglobulin, called Cytotect® CP, in which β-propiolactone treatment is omitted. Here we show that Cytotect® CP inhibits PHA-driven T-cell proliferation and cytokine production with similar efficacy as Hepatect® CP, whereas the former Cytotect® does not. In addition, Cytotect® CP inhibits allogeneic T-cell responses better than Cytotect®. Our results advocate the use of hyperimmunoglobulins that have not been exposed to β-propiolactone in order to benefit from their immunomodulatory properties.

β-propiolactone, Hyperimmunoglobulin, Immunomodulation, Intravenous immunoglobulin, T-cell responses
dx.doi.org/10.1016/j.intimp.2014.01.007, hdl.handle.net/1765/66179
International Immunopharmacology
Department of Gastroenterology & Hepatology

van Gent, R, Jaadar, H, Tjon, S.W.A, Mancham, S, & Kwekkeboom, J. (2014). T-cell inhibitory capacity of hyperimmunoglobulins is influenced by the production process. International Immunopharmacology, 19(1), 142–144. doi:10.1016/j.intimp.2014.01.007